23 Results

People

  1. Horwitz
    Horwitz
  2. Kobos
    Kobos
  3. Moskowitz
    Moskowitz
  4. Shukla
    Shukla
  5. Steinherz
    Steinherz
  6. Steinherz
    Steinherz
  7. Usmani
    Usmani
  8. Zelenetz
    Zelenetz
  9. Afifi
    Afifi
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (14)
  2. Center for Hematologic Malignancies (12)
  3. Hematologic Malignancies, Division of (11)
  4. Lymphoma (4)
  5. Pediatrics, Department of (4)
  6. Adult Leukemia (3)
  7. Solid Tumor Oncology Division (3)
  8. Biostatistics Service (2)
  9. Department of Pathology and Laboratory Medicine (2)
  10. Epidemiology and Biostatistics (2)
  1. "relapsed"
Formats
  1. Journal Article (17)
  2. Meeting Abstract (2)
  3. Review (2)
  4. Conference Paper (1)
  5. Editorial (1)
Groups
  1. Department of Medicine (14)
  2. Center for Hematologic Malignancies (12)
  3. Hematologic Malignancies, Division of (11)
  4. Lymphoma (4)
  5. Pediatrics, Department of (4)
  6. Adult Leukemia (3)

More Groups

People
  1. Andrew Zelenetz (2)
  2. Craig Moskowitz (2)
  3. Eytan Stein (2)
  4. Laurel Steinherz (2)
  5. Neerav Shukla (2)
  6. Peter Steinherz (2)

More People

Years
  1. 2024 (3)
  2. 2023 (3)
  3. 2021 (1)
  4. 2020 (2)
  5. 2018 (1)
  6. 2016 (1)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (5)
  2. Pediatric Blood and Cancer (5)
  3. Annals of Oncology (1)
  4. Annals of Pharmacotherapy (1)
  5. Biology of Blood and Marrow Transplantation (1)
  6. Current Treatment Options in Oncology (1)

More Publications

Publishers
  1. Elsevier Inc. (7)
  2. Wiley Periodicals, Inc (5)
  3. John Wiley & Sons (2)
  4. Springer (2)
  5. Elsevier Ltd (1)
  6. Future Medicine (1)

More Publishers

Results (23)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: A single group, open-label, phase 1/2 trial
    Journal Article

    Gurumurthi, A.; Chin, C. K.; Feng, L.; Fowler, N. H.; Strati, P.; Hagemeister, F. B.; Fayad, L. E.; Westin, J. R.; Obi, C.; Arafat, J.; more...
    eClinicalMedicine (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma
    Journal Article

    Dima, D.; Mansour, R.; Davis, J. A.; Minchak, M.; Goel, U.; Atallah, R.; Logan, E.; Tabak, C.; Rashid, A.; Ahmed, N.; more...
    European Journal of Haematology (2024)

    Fulltext@MSK | Save
  • SOHO state of the art updates and next questions: Will CAR-T replace ASCT in NDMM
    Review

    Jurgens, E.; Usmani, S. Z.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy
    Editorial

    Luttwak, E.; Smith, M. R.; Zelenetz, A. D.
    Expert Opinion on Pharmacotherapy (2023)

    Fulltext@MSK | Save
  • A clinical and correlative study of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for lenalidomide refractory multiple myeloma in first relapse
    Journal Article

    Bhutani, M.; Foureau, D. M.; Robinson, M.; Guo, F.; Fesenkova, K.; Atrash, S.; Paul, B.; Varga, C.; Friend, R.; Pineda-Roman, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Advances in the clinical management of high-risk Wilms tumors
    Review

    Ortiz, M. V.; Koenig, C.; Armstrong, A. E.; Brok, J.; de Camargo, B.; Mavinkurve-Groothuis, A. M. C.; Herrera, T. B. V.; Venkatramani, R.; Woods, A. D.; Dome, J. S.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force
    Journal Article

    Whittle, S. B.; Offer, K.; Roberts, R. D.; LeBlanc, A.; London, C.; Majzner, R. G.; Huang, A. Y.; Houghton, P.; Sweet Cordero, E. A.; Grohar, P. J.; more...
    Pediatric Blood and Cancer (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of asciminib in heavily pretreated patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) with sensitivity to tyrosine kinase inhibitors (TKIs)
    Meeting Abstract

    Hughes, T.; Mauro, M.; Kim, D. W.; Cortes, J.; Réa, D.; Minami, H.; Breccia, M.; DeAngelo, D.; Hochhaus, A.; Goh, Y. T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Ivosidenib (IVO) prior to hematopoietic cell transplant (HCT) for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML) who cannot tolerate intensive chemotherapy (IC)
    Meeting Abstract

    DiNardo, C. D.; Stein, E. M.; Pigneux, A.; Altman, J. K.; Collins, R.; Erba, H. P.; Watts, J. M.; Uy, G. L.; Wu, B.; Choe, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia
    Journal Article

    Stein, E. M.
    Future Oncology (2018)

    Fulltext@MSK | Save